ArticleERJ open research2026
Selexipag for the treatment of schistosomiasis-associated pulmonary arterial hypertension: the SELSCH study.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) is one of the most prevalent forms of PAH in Brazil. However, no prospective data are available for evaluating the efficacy of PAH drugs in the treatment of Sch-PAH. Does selexipag improve pulmonary vascular resistance (PVR) in Sch-PAH patients? Methods: The SELSCH study was a single-centre, single-arm, open-label prospective study with the aim of evaluating selexipag for the treatment of Sch-PAH. The primary end-point was a reduction in PVR at week 16. Results: 20 Sch-PAH patients completed the SELSCH study. 20% (n=4) of them used sildenafil as baseline monotherapy, 10% (n=2) used an endothelin receptor antagonist (ERA) and 65% (n=13) of the patients used combination therapy (sildenafil+ERA) before the addition of selexipag. One patient (5%) started selexipag as PAH monotherapy. Selexipag reduced PVR from 9.4±3.93 to 7.75±3.81 WU (p=0.048) and improved World Health Organization Functional Class (p=0.021). There was an increase in cardiac index (from 2.5±0.86 to 2.9±0.67 L·min Conclusion: Selexipag was effective in the treatment of the 20 Sch-PAH studied patients since it significantly reduced PVR by 18%. Selexipag was well tolerated, despite the occurrence of side-effects during the titration phase. The SELSCH study is the first to demonstrate the prospective efficacy of specific PAH therapy in patients with schistosomiasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.